|
|
|
|
|
|
|
||
Original Article |
Stimulates Osteoclast Differentiation by a Mechanism Independent of the Odf/Rankl–Rank Interaction
suda{at}showa-u.ac.jp
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
) appeared within 3 d. Tartrate-resistant acid phosphatase–positive osteoclasts were also formed when M-BMM were further cultured for 3 d with mouse tumor necrosis factor 
(TNF-) in the presence of M-CSF. Osteoclast formation induced by TNF- was inhibited by the addition of respective antibodies against TNF receptor 1 (TNFR1) or TNFR2, but not by osteoclastogenesis inhibitory factor (OCIF, also called OPG, a decoy receptor of ODF/RANKL), nor the Fab fragment of anti–RANK (ODF/RANKL receptor) antibody. Experiments using M-BMM prepared from TNFR1- or TNFR2-deficient mice showed that both TNFR1- and TNFR2-induced signals were important for osteoclast formation induced by TNF-. Osteoclasts induced by TNF- formed resorption pits on dentine slices only in the presence of IL-1. These results demonstrate that TNF- stimulates osteoclast differentiation in the presence of M-CSF through a mechanism independent of the ODF/RANKL–RANK system. TNF- together with IL-1 may play an important role in bone resorption of inflammatory bone diseases.
Key Words: bone resorption • tumor necrosis factor receptor • nuclear factor-
B • macrophage colony-stimulating factor • interleukin-1
We have also shown that osteoblasts/stromal cells play an integral role in inducing osteoclast function 1920. When purified osteoclasts formed in cocultures were further cultured on dentine slices, they rapidly underwent apoptosis and failed to form resorption pits on the slices. Osteoblasts/stromal cells added to purified osteoclasts greatly stimulated the survival and resorption activity of osteoclasts through cell-to-cell contact. Both IL-1
TNF-
In the present study, the role of TNF-
Mouse M-BMM
Introduction
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
Osteoclasts, the multinucleated giant cells that resorb bone, develop from hemopoietic cells of the monocyte/macrophage lineage 12. Osteoblasts or bone marrow stromal cells are involved in osteoclastogenesis through a mechanism involving cell-to-cell contact with osteoclast progenitor cells. We previously proposed a hypothesis that osteoblasts/stromal cells express osteoclast differentiation factor (ODF) in response to several osteotropic factors in supporting osteoclast differentiation from their precursors 134. This working hypothesis was proved by the recent discovery of a new member of the TNF ligand family, [ODF 5, also called osteoprotegerin ligand (OPGL) 6/TNF-related activation-induced cytokine (TRANCE) 7/receptor activator of nuclear factor-B ligand (RANKL) 8] as a membrane-associated factor 34. Osteoclast precursors that express RANK 91011, a TNF receptor family member, recognize ODF/RANKL through cell-to-cell interaction with osteoblasts/stromal cells, and differentiate into osteoclasts in the presence of macrophage CSF (M-CSF, also called CSF-1) 56. M-CSF has been shown to be an essential factor for osteoclast formation in vivo and in vitro 1213. Osteoclastogenesis inhibitory factor [OCIF, also called osteoprotegerin (OPG)/TNF receptor-like molecule 1] is a soluble decoy receptor for ODF/RANKL 1415161718. Nuclear factor B (NF-B) and c-Jun NH2-terminal kinase (JNK) activated by the RANK-mediated signals in osteoclast precursors appear to be involved in their differentiation into osteoclasts 78. and soluble ODF/soluble RANKL (sODF/sRANKL) prolonged the survival of purified osteoclasts and induced their pit-forming activity 921. OCIF/OPG inhibited both the survival and resorption activity of osteoclasts supported by not only sODF/sRANKL 9, but also osteoblasts/stromal cells 4. Fuller et al. 22 reported that TRANCE (ODF/RANKL) is involved in osteoclast activation induced by osteoblasts treated with parathyroid hormone. It was also demonstrated that OPGL (ODF/RANKL) activated mature osteoclasts in vitro, and that administration of OPGL induced rapid increases in blood-ionized calcium levels in mice 23. These results suggest that ODF/RANKL expressed by osteoblasts/stromal cells is responsible for inducing the differentiation, survival, and activation of osteoclasts 34. IL-1 can be substituted for ODF/RANKL in inducing the survival and activation of osteoclasts 21. , which is produced by many types of cells, including monocytes and macrophages, has been proposed to be involved in bone resorption, particularly in inflammatory bone diseases. Merkel et al. 24 demonstrated that TNF- is involved in orthopedic osteolysis induced by implant-derived particles. It was also reported that TNF- and IL-1 play important roles in bone loss associated with osteoporosis and periodontitis 2526. Lipopolysaccharide-stimulated osteoclastogenesis has been shown to be mediated by TNF- 27. In addition, Pfeilschifter et al. 28 reported that human TNF- and IL-1 stimulated formation of multinucleated cells with the characteristics of osteoclasts in human bone marrow cultures. TNF- induces a number of biological responses via two cell-surface receptors termed TNFR1 and TNFR2 (also called TNFR p55 and TNFR p75, respectively) 293031. Both TNFR1 and TNFR2 can transduce intracellular signals that stimulate the proteolytic breakdown of IB, a cytoplasmic inhibitor of NF-B 32333435. The activated NF-B is then translocated into the nucleus, where it induces the transcription of several TNF-–responsive genes. In addition, the binding of TNF- to TNFR1 triggers programmed cell death in many cells. This process depends on the presence of the "death domain" located in the cytoplasmic region of TNFR1, which is absent in TNFR2 3637. It is well established that mouse TNF- binds to both mouse TNFR1 and TNFR2 with high affinity, while human TNF- binds to mouse TNFR1 with higher affinity than to mouse TNFR2 2930. in osteoclast differentiation was studied in detail. Mouse TNF- strongly stimulated the differentiation of M-CSF–dependent mouse bone marrow macrophages (M-BMM) into osteoclasts in the presence of M-CSF. Human TNF- induced only a few osteoclasts in the M-BMM cultures. OCIF/OPG did not inhibit TNF-–induced osteoclast formation. We report here that the ODF/RANKL–RANK interaction is not the sole pathway that leads osteoclast progenitors to differentiation into osteoclasts in vitro; the TNF-–TNFR1/TNFR2 interaction can be substituted for the ODF/RANKL–RANK interaction in inducing osteoclast differentiation under some pathological conditions.
Materials and Methods
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
Antibodies and Chemicals.
Recombinant mouse sODF/sRANKL and human OCIF/OPG were prepared as described previously 516. Recombinant proteins of mouse and human TNF-, and human IL-1 were obtained from R & D Systems, Inc. Human M-CSF was obtained from Yoshitomi Pharmaceutical Co. Anti–mouse TNFR1 and TNFR2 antibodies were purchased from Genzyme Diagnostics. The Fab fragment of anti–RANK polyclonal antibody and nonimmunized rabbit immunoglobulin were prepared using the immunopure Fab preparation kit (Pierce) as described previously 10. Anti–Mac-1, Moma-2, and F4/80 rat monoclonal antibodies were obtained from Serotec. (3-[125I] iodotyrosyl12) Human calcitonin (specific activity, 74 TBqmmol) was obtained from Amersham International. Culture.
5–8-wk-old male ddY and C57BL/6J mice and newborn ddY mice were obtained from Sankyo Labo Service Co. C57BL/6J mice, in which the TNFR1 or TNFR2 gene had been deleted, were obtained from Jackson ImmunoResearch Laboratories, Inc. Bone marrow cells prepared from the tibia of ddY mice, TNFR1-deficient mice [TNFR1(–/–)], or TNFR2-deficient mice [TNFR2(–/–)] were suspended in MEM containing 10% fetal bovine serum (JRH Biosciences), and cultured in 48-well plates (1.5 x 105 cells/0.25 ml per well) in the presence of M-CSF (100 ng/ml). After culturing for 3 d, nonadherent cells were completely removed from the culture by pipetting. Characteristics of adherent cells were examined by staining with antibodies against Mac-1, Moma-2, and F4/80 antigens using a Vectastain ABC AP kit and Vector Red (Vector Laboratories, Inc.). Positive cells were stained red (see Fig. 1). As almost all of the adherent cells were positive for these antibodies, we called the adherent cells M-BMM. M-BMM were further cultured for 3 d with either cytokine of sODF/sRANKL, mouse TNF-, human TNF-, or IL-1 in the presence or absence of OCIF/OPG and/or M-CSF. Some cultures were also treated with anti–mouse TNFR1 or TNFR2 antibody, or the Fab fragment of anti–RANK antibody. Cells were then fixed and stained for tartrate-resistant acid phosphatase (TRAP) as described previously 38. Cells were also stained for alkaline phosphatase (a marker enzyme of osteoblasts) as described previously 38. Positive cells appeared as blue cells. The number of TRAP-positive cells, including mononuclear and multinucleated cells, was scored under microscopic examination. In some experiments, TRAP-positive cells containing more than three nuclei were also counted as TRAP-positive multinucleated cells.
|
Pit Formation Assay.
To determine resorption activity of TRAP-positive cells, bone marrow cells of ddY mice (2 x 105 cells/well) were plated on dentine slices (4 mm in diameter) that had been placed in 48-well culture plates. Bone marrow cells were first cultured with M-CSF (100 ng/ml) for 3 d. The slices, on which M-BMM were formed, were then well washed with MEM to remove nonadherent cells, and further cultured with or without cytokines for an additional 3 d. Some dentine slices were subjected to TRAP staining. The remaining slices were cleaned by ultrasonication in 1 M NH4OH to remove adherent cells and stained with Mayer's hematoxylin to visualize resorption pits as described 38. The number of TRAP-positive cells on the slices and that of resorption pits were counted under microscopic examination.
Survival Assay of Osteoclasts.
Osteoblasts obtained from the calvaria of newborn ddY mice and bone marrow cells from ddY mice were cocultured in MEM containing 10% fetal bovine serum, 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] (10–8 M) (Wako Pure Chemical Co.), and prostaglandin E2 (10–6 M) (Sigma Chemical Co.) in 100-mm–diameter dishes coated with Type I collagen gels (Nitta Gelatin Co.) as described previously 38. Osteoclasts formed within 6 d were recovered from the dishes by treating with 0.2% collagenase (crude osteoclasts). To purify osteoclasts, the crude osteoclast preparation was replated and cultured for 8 h. Osteoblasts were then removed by treating with PBS containing 0.001% pronase E and 0.02% EDTA 38. Some of the cultures were then stained for TRAP. The other cultures were further incubated for 36 h in the presence or absence of mouse TNF- (20 ng/ml), human TNF- (20 ng/ml), IL-1 (10 ng/ml), or sODF/sRANKL (100 ng/ml), and stained for TRAP. TRAP-positive multinucleated cells containing more than three nuclei were counted as living osteoclasts.
Polymerase Chain Reaction Amplification of Reverse-transcribed mRNA.
For semiquantitative reverse-transcriptase PCR (RT-PCR) analysis, total RNA was extracted using Trizol solution (GIBCO BRL) from freshly isolated bone marrow cells, M-BMM, and purified osteoclasts. Purified osteoclasts were obtained from cocultures of mouse bone marrow cells and calvarial osteoblasts as described previously 21. First strand cDNA was synthesized from total RNA with random primers and was subjected to PCR amplification with EX Taq polymerase (Takara Shuzo) using specific PCR primers: mouse TNFR1, 5'-GAGTGCTGACCTATAACACATTCCT-3' (forward, nucleotides 3152–3176) and 5'-CATCTTGCCAGTTCAAAACTAACTT-3' (reverse, nucleotides 3553–3577); mouse TNFR2, 5'-CATTCTAAGAACAATTCCATCTGCT-3' (forward, nucleotides 246–270) and 5'-GGGTACTGGAGACAGGAGAACTAA-3' (reverse, nucleotides 961–984); mouse RANK, 5'-ACACCTGGAATGAAGAAGATAAATG-3' (forward, nucleotides 260–284) and 5'-AGCCACTACTACCACAGAGATGAAG-3' (reverse, nucleotides 684–708); mouse c-Fms, 5'-AACAAGTTCTACAAACTGGTGAAGG-3' (forward, nucleotides 2653–2677) and 5'-GAAGCCTGTAGTCTAAGCATCTGTC-3' (reverse, nucleotides 3381–3405); mouse glyceraldehyde-3-phosphate dehydrogenase, 5'-ACCACAGTCCATGCCATCAC-3' (forward, nucleotides 566–585) and 5'-TCCACCACCCTGTTGCTGTA-3' (reverse, nucleotides 998–1017). The PCR products were separated by electrophoresis on a 2% agarose gel.
Electrophoretic Mobility Shift Assay.
Mouse M-BMM were treated with sODF/sRANKL (100 ng/ml), mouse TNF- (20 ng/ml), or human TNF- (20 ng/ml) for 1 h. Nuclear extracts were then prepared from M-BMM as described previously 39. An NF-B–binding oligonucleotide sequence 5'-AGCTTGGGGACTTTCCGAG-3' was used as a radioactive DNA probe. DNA binding reaction was performed at room temperature in a volume of 30 µl, which contained the binding buffer (10 mM Tris/HCl, pH 7.5, 1 mM EDTA, 4% glycerol, 100 mM NaCl, 5 mM DTT, 100 mg/ml of BSA), 3 µg of poly(dI-dC), 105 cpm of a 32P-labeled probe, and 8 µg of nuclear proteins. After incubation for 15 min, the samples were electrophoresed on native 5% acrylamide/0.25 x Tris-borate-EDTA gels. The gels were dried and exposed to x-ray film.
Statistical Analysis.
Significance of differences was determined using Student's t test.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
. Typically, 104 M-BMM were obtained when 105 bone marrow cells were cultured for 3 d in the presence of M-CSF. There were very few alkaline phosphatase–positive stromal cells detectable in the M-BMM preparation (data not shown).
When M-BMM were further cultured with sODF/sRANKL and M-CSF, TRAP-positive mononuclear and multinucleated cells were formed within 3 d (Fig. 2A and Fig. B). In the absence of M-CSF, most of the M-BMM died within 3 d. No TRAP-positive cells were formed when M-CSF was not added, even in the presence of sODF/sRANKL. Although varied in each experiment, 40–80% of the M-BMM usually differentiated into TRAP-positive cells in response to sODF/sRANKL and M-CSF. When nonadherent cells, which were recovered from bone marrow cultures treated for 3 d with M-CSF, were further cultured for 3 d with ODF/RANKL and M-CSF, only a few TRAP-positive cells were formed (data not shown). This suggests that osteoclast progenitors are present preferentially as adherent cells in M-CSF–treated bone marrow cells. Surprisingly, mouse TNF- stimulated TRAP-positive cell formation from M-BMM in the presence of M-CSF in a dose-dependent manner (Fig. 2A and Fig. C). Morphology of TRAP-positive cells induced by mouse TNF- was quite similar to that induced by sODF/sRANKL (Fig. 2 B). Repeated experiments showed that 3–5% of the TRAP-positive cells induced by either mouse TNF- or ODF/RANKL were multinucleated cells, which contained more than three nuclei. In contrast, human TNF- at 20 ng/ml induced a few TRAP-positive mononuclear cells in M-BMM cultures (Fig. 2 B). Neither human nor mouse TNF- induced apoptosis of M-BMM in the presence or absence of M-CSF. No TRAP-positive cells were formed in M-BMM cultures treated with IL-1 at 10 ng/ml even in the presence of M-CSF (Fig. 2A and Fig. B). Addition of 1,25(OH)2D3 at 10–8 M to the M-BMM cultures also failed to induce TRAP-positive cells, irrespective of the presence or absence of M-CSF (Fig. 2A and Fig. B). Alkaline phosphatase–positive cells were not detected in the M-BMM preparation after culture for 3 d with 1,25(OH)2D3 and M-CSF (Fig. 2 B). Mouse TNF- (20 ng/ml) stimulated TRAP-positive cell formation in cultures of mouse spleen cells or whole bone marrow cells in the presence of M-CSF (100 ng/ml) (data not shown). We used M-BMM instead of whole bone marrow cells in this experiment to avoid contamination of cells other than osteoclast progenitors.
|
expressed these mRNAs (Fig. 3 A). Both M-BMM and osteoclasts expressed c-Fms mRNA as well. Freshly isolated bone marrow cells expressed mRNAs of TNFR1, TNFR2, RANK, and c-Fms only weakly, when compared with M-BMM and osteoclasts (Fig. 3 A). An electrophoretic mobility shift assay revealed that mouse TNF-, human TNF-, and sODF/sRANKL all activated NF-B in M-BMM (Fig. 3 B).
|
irrespective of the presence or absence of OCIF/OPG (Fig. 4 A, bottom). Although these results suggest that TNF- induces osteoclast differentiation through TNFR1/TNFR2, there were still two possibilities that TNF- directly binds to RANK or TNF- increases endogenous production of some factor(s) that can interact with RANK. To exclude these possibilities, the Fab fragment of polyclonal antibodies against the extracellular domain of RANK was used in the next experiment. We previously reported that the anti–RANK antibody induced osteoclastogenesis in the presence of M-CSF, probably through clustering of RANK 10. In contrast, the Fab fragment of the antibody blocked the binding of ODF/RANKL to RANK, causing the inhibition of the sODF/sRANK-mediated osteoclastogenesis 10. The Fab fragment of the anti–RANK antibody inhibited TRAP-positive cell formation induced by sODF/sRANK (Fig. 4 B). In contrast, the Fab fragment of the anti–RANK antibody showed no inhibitory effect on mouse TNF-–induced TRAP-positive cell formation in M-BMM cultures. These results indicate that TNF- stimulates TRAP-positive cell formation by a mechanism independent of the ODF/RANKL–RANK interaction.
|
cultures treated with mouse TNF- or sODF/sRANKL in the presence of M-CSF (Fig. 5 A). Both antibodies showed no inhibitory effect on the sODF/sRANKL-induced TRAP-positive cell formation, but each of the two antibodies strongly inhibited TRAP-positive cell formation induced by mouse TNF- (Fig. 5 A). To further confirm the possibility that both TNFR1 and TNFR2 play important roles in TNF-–induced TRAP-positive cell formation, M-BMM were prepared from TNFR1(–/–), TNFR2(–/–), and the control C57BL/6J (wild type) mice, and compared their capacity to differentiate into TRAP-positive cells in the presence of mouse TNF- plus M-CSF or sODF/sRANKL plus M-CSF (Fig. 5 B). In the presence of sODF/sRANKL, the number of TRAP-positive cells formed from TNFR1(–/–) and TNFR2(–/–) M-BMM culture was similar to that from the control (wild type) M-BMM (Fig. 5 B). In contrast, no TRAP-positive cells were observed in TNFR1(–/–) M-BMM cultures treated with mouse TNF- (Fig. 5 B). TRAP-positive cell formation induced by mouse TNF- was markedly reduced in TNFR2(–/–) M-BMM cultures in comparison with that in the control (wild type) cultures. These results confirmed that both TNFR1- and TNFR2-mediated signals were important for TNF-–induced osteoclast differentiation.
|
together with M-CSF even in the presence of OCIF/OPG (Fig. 6 A). In agreement with previous findings 5, numerous grains of the binding of labeled calcitonin were observed on TRAP-positive cells induced by sODF/sRANKL in the presence of M-CSF (Fig. 6 B). However, no calcitonin receptor-positive cells appeared in M-BMM cultures treated with sODF/sRANKL plus M-CSF in the presence of OCIF/OPG (Fig. 6 C). The binding of [125I]-labeled calcitonin to TRAP-positive cells was inhibited by an excess amount of unlabeled calcitonin simultaneously added (data not shown), suggesting that TRAP-positive cells induced by mouse TNF- as well as sODF/RANKL expressed calcitonin receptors.
|
, M-CSF, and sODF/sRANKL similarly stimulated the survival of purified osteoclasts via the respective receptors 921. Using purified osteoclasts, we next examined whether TNF- supports the survival of osteoclasts (Fig. 7). Most of the osteoclasts died within 36 h after removal of osteoblasts in the presence and absence of OCIF/OPG. Treatment of purified osteoclast preparations with mouse TNF- stimulated the survival of osteoclasts. OCIF/OPG showed no inhibitory effects on the survival of osteoclasts supported by mouse TNF- (Fig. 7). In agreement with previous finding 9, sODF/sRANKL and IL-1 stimulated the survival of purified osteoclasts. OCIF/ OPG strongly inhibited the survival of osteoclasts supported by sODF/sRANKL but not by IL-1 (Fig. 7).
|
, or sODF/sRANKL 91921. When M-BMM were prepared on dentine slices, and cultured with mouse TNF-, IL-1, or mouse TNF- plus IL-1 in the presence of M-CSF and OCIF/OPG, a similar number of TRAP-positive cells appeared on dentine slices in response to mouse TNF- irrespective of the presence and absence of IL-1 (Fig. 8A and Fig. B). However, resorption pits on the slices were detected only in the presence of both mouse TNF- and IL-1 (Fig. 8A and Fig. B). These results suggest that TNF- stimulates the differentiation and survival of osteoclasts, but not the function of osteoclasts.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
together with M-CSF induces TRAP-positive cell formation in M-BMM cultures without any help of osteoblasts/stromal cells. Alkaline phosphatase–positive cells were seldom detected in the M-BMM preparation even after culture for an additional 3 d. No TRAP-positive cells were formed in the cultures of the M-BMM preparation treated with 1,25(OH)2D3 in the presence or absence of M-CSF. A recent study on vitamin D receptor knockout mice proved that the target cells of 1,25(OH)2D3 in inducing osteoclast formation are osteoblasts/stromal cells, but not osteoclast progenitors 41. These results suggest that even if a small number of stromal cells were present in the M-BMM preparation, they could not support osteoclast formation.
Like authentic osteoclasts, TRAP-positive cells formed in response to TNF- and M-CSF expressed calcitonin receptors. TNF-–induced TRAP-positive cells formed resorption pits only in the presence of IL-1. This property of TRAP-positive cells induced by TNF- is recognized in ODF/RANKL-induced osteoclasts as well 1921. M-CSF was essentially required for osteoclast formation induced by TNF- as in sODF/sRANKL-induced osteoclast formation. These results indicate that TNF-–induced TRAP-positive cells in M-BMM cultures satisfy major criteria for osteoclasts. OCIF/OPG and the Fab fragment of anti–RANK antibody did not inhibit the TNF-–induced TRAP-positive and calcitonin receptor-positive osteoclast formation. Using RT-PCR, we found that M-BMM expressed ODF/RANKL mRNA, but its level was very low and was not upregulated by adding mouse TNF- (data not shown). These results further confirm that ODF/RANKL is not involved in the TNF-–induced osteoclast formation in M-BMM cultures. In our preliminary experiments, human TNF- stimulated the formation of TRAP- and vitronectin receptor (23C6)–positive osteoclast-like cells in cultures of human peripheral blood mononuclear cells even in the presence of OCIF/OPG (data not shown). These results suggest that the ODF/RANKL–RANK signaling system is not the sole pathway for inducing osteoclast differentiation in vitro (Fig. 9).
|
expressed both TNFR1 and TNFR2. Activation of NF-B in M-BMM was induced not only by mouse TNF-, but also human TNF-. However, the potency of human TNF- to induce TRAP-positive osteoclast formation in M-BMM cultures was much weaker than that of mouse TNF-. Anti–TNFR1 antibody completely inhibited osteoclast formation induced by mouse TNF-, but not osteoclast formation by sODF/sRANKL. M-BMM prepared from TNFR1(–/–) mice did not differentiate into TRAP-positive cells in response to mouse TNF-. These results suggest that TNFR1-mediated signals are essential for TRAP-positive cell formation induced by TNF-. Furthermore, addition of anti–TNFR2 antibody to M-BMM cultures significantly inhibited TRAP-positive osteoclast formation induced by mouse TNF-. In addition, TRAP-positive osteoclast formation induced by mouse TNF- was markedly reduced in TNFR2(–/–) M-BMM cultures. These results suggest that TNFR2-mediated signals play important roles in osteoclast differentiation. Collectively, both signals mediated by TNFR1 and TNFR2 appear to be required for inducing osteoclast formation at the level similar to ODF/RANKL-induced osteoclast formation (Fig. 9). Using the anti–TNFR1 and –TNFR2 antibody, it was clearly shown that only TNFR1-mediated signals led to the endotoxin-induced shock and protective response against Listeria monocytogenes infection, and both TNFR1- and TNFR2-mediated signals were required for the development of TNF-–induced skin necrosis in mice 42. Abu-Amer et al. 27 reported that osteoclastogenesis induced by lipopolysaccharides is mediated by TNF- via TNFR1. They also showed that human as well as mouse TNF- stimulated the expression of c-Src, a marker protein of osteoclasts, in mouse bone marrow macrophages 27. These findings support the conclusion that TNFR1-mediated signals are essential for osteoclast differentiation.
We previously reported that purified osteoclasts rapidly underwent apoptosis and did not form resorption pits on dentine slices 19. IL-1 as well as sODF/sRANKL induced the survival and pit-forming activity of purified osteoclasts 921. The present study showed that the survival of purified osteoclasts was stimulated by human as well as mouse TNF-. However, resorption pits were not formed on dentine slices in M-BMM cultures treated with mouse TNF- and M-CSF. Resorption pits were observed on dentine slices in the M-BMM culture further treated with IL-1. These results suggest that TNF- is capable of stimulating the differentiation and survival of osteoclasts, but not the pit-forming activity of osteoclasts. On the other hand, ODF/RANKL supports all the processes of differentiation, survival, and activation of osteoclasts (Fig. 9).
Determination of signals involved in osteoclast differentiation is an important issue in the research on osteoclast biology. At present, two signals, NF-B and JNK, have been proposed to be involved in osteoclast differentiation. Hsu et al. 11 reported that ODF/RANKL stimulated JNK activity of murine myeloid RAW-264.7 cells and induced differentiation of these cells into osteoclasts. Activation of NF-B in RAW-264.7 cells was not induced by ODF/RANKL. This indicates that the signals mediated by JNK rather than NF-B are important for ODF/RANKL-induced osteoclast differentiation in RAW-264.7 cells. In our experiments, IL-1 activated NF-B in M-BMM (data not shown), but failed to induce osteoclast differentiation in M-BMM cultures. These results suggest that some other signals than NF-B may play an important role in osteoclast differentiation. RAW-264.7 cells differentiated into TRAP-positive cells in response to mouse TNF- as well as ODF/RANKL (data not shown). Possible involvement of JNK and NF-B in osteoclastogenesis is currently under investigation in our laboratories.
Mounting evidence has demonstrated that TNF receptor family members interact with TNF receptor–associated factors (TRAFs) to modulate JNK and NF-B activity as well as apoptosis in the target cells 4344. TRAF2 has been shown to be an adaptor protein for TNFR1- and TNFR2-mediated signals in the target cells 4344. Recent studies have demonstrated that the cytoplasmic tail of RANK interacts with TRAF1, TRAF2, TRAF3, TRAF5, and TRAF6 45464748. Recently, it was reported that TRAF6 knockout mice developed severe osteopetrosis 4950. Similar numbers of TRAP-positive osteoclasts were observed in TRAF6 knockout mice and normal mice, but osteoclasts in TRAF6-deficient mice did not form ruffled borders, structures necessary for bone resorption 49. IL-1 receptors have been shown to use TRAF6 as a signal-transducing molecule in the target cells 51. We previously showed that IL-1 activated NF-B in purified osteoclasts 39. IL-1 also induced pit-forming activity of osteoclasts placed on dentine slices 21. However, IL-1 failed to induce osteoclast differentiation in M-BMM cultures. These results suggest that TRAF6 is a common signaling molecule responsible for osteoclast activation induced by ODF/RANKL and IL-1. TRAF2 and/or its related TRAFs may be involved in the differentiation of osteoclasts. Thus, ODF/RANKL–RANK interaction induces signals necessary for both differentiation and activation of osteoclasts (Fig. 9).
TNF- stimulates osteoclastogenesis in the absence of ODF/RANKL in vitro. However, this is not consistent with the finding that the disruption of the ODF/RANKL gene in mice showed a complete lack of osteoclasts in bone 40. Recently, it was reported that TNF-– and IL-1–induced bone resorption in mice was inhibited by concomitant treatment with OCIF/OPG 52. Our preliminary experiments showed that TNF- as well as IL-1 upregulated expression of ODF/RANKL mRNA in osteoblasts/stromal cells (data not shown), suggesting that a part of bone resorption induced by TNF- and IL-1 could be inhibited by OCIF/OPG. In fact, we reported that bone resorption induced by parathyroid hormone and 1,25(OH)2D3 was completely inhibited by adding OCIF/OPG in an organ culture system, but the inhibition by OCIF/OPG of IL-1–induced bone resorption was only partial 53. Ammann et al. 54 also reported that transgenic mice insensitive to TNF due to the overexpression of soluble TNF receptors are protected against bone loss due to estrogen deficiency. These results suggest that TNF- and IL-1 are directly involved in pathologically occurring bone resorption observed in inflammatory and metabolic bone diseases such as rheumatoid arthritis, periodontitis, and/or postmenopausal osteoporosis 24252627. Further studies will elucidate the biological significance of osteoclast differentiation and function stimulated by a combination of TNF- and IL-1 in pathological bone resorption.
|
Acknowledgments |
|---|
Submitted: 6 July 1999
Revised: 22 September 1999
Accepted: 26 October 1999
,25(OH)2D3, 1,25-dihydroxyvitamin D3; JNK, c-Jun NH2-terminal kinase; M-BMM, M-CSF–dependent bone marrow macrophages; M-CSF, macrophage CSF; NF-B, nuclear factor B; OCIF, osteoclastogenesis inhibitory factor; ODF, osteoclast differentiation factor; OPGL, osteoprotegerin ligand; RANKL, receptor activator of NF-B ligand; RT-PCR, reverse-transcriptase PCR; TRAP, tartrate-resistant acid phosphatase.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Suda T., Takahashi N. & Martin T.J.. Modulation of osteoclast differentiation, Endocr. Rev, 13, 1992, 66–80.
Chambers T.J., Revell P.A., Fuller K. & Athanasou N.A.. Resorption of bone by isolated rabbit osteoclasts, J. Cell Sci, 66, 1984, 383–399.[Abstract]
Takahashi N., Udagawa N. & Suda T.. A new member of TNF ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function, Biochem. Biophys. Res. Commun, 256, 1999, 449–455.[Medline]
Suda T., Takahashi N., Udagawa N., Jimi E., Gillespie M.T. & Martin T.J.. Modulation of osteoclast differentiation and function by the new members of the TNF receptor and ligand families, Endocr. Rev, 20, 1999, 345–357.
Yasuda H., Shima N., Nakagawa N., Yamaguchi K., Kinosaki M., Mochizuki S., Tomoyasu A., Yano K., Goto M. & Murakami A.. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL, Proc. Natl. Acad. Sci. USA., 95, 1998, 3597–3602.
Lacey D.L., Timms E., Tan H.L., Kelley M.J., Dunstan C.R., Burgess T., Elliott R., Colombero A., Elliott G. & Scully S.. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation, Cell., 93, 1998, 165–176.[Medline]
Wong B.R., Rho J., Arron J., Robinson E., Orlinick J., Chao M., Kalachikov S., Cayani E., Bartlett F.S. III & Frankel W.N.. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells, J. Biol. Chem, 272, 1997, 25190–25194.
Anderson D.M., Maraskovsky E., Billingsley W.L., Dougall W.C., Tometsko M.E., Roux E.R., Teepe M.C., DuBose R.F., Cosman D. & Galibert L.. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function, Nature., 390, 1997, 175–179.[Medline]
Jimi E., Akiyama S., Tsurukai T., Okahashi N., Kobayashi K., Udagawa N., Nishihara T., Takahashi N. & Suda T.. Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function, J. Immunol, 163, 1999, 434–442.
Nakagawa N., Kinosaki M., Yamaguchi K., Shima N., Yasuda H., Yano K., Morinaga T. & Higashio K.. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis, Biochem. Biophys. Res. Commun, 253, 1998, 395–400.[Medline]
Hsu H., Lacey D.L., Dunstan C.R., Solovyev I., Colombero A., Timms E., Tan H.L., Elliott G., Kelley M.J. & Sarosi I.. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand, Proc. Natl. Acad. Sci. USA., 96, 1999, 3540–3545.
Kodama H., Nose M., Niida S. & Yamasaki A.. Essential role of macrophage colony-stimulating factor in the osteoclast differentiation supported by stromal cells, J. Exp. Med, 173, 1991, 1291–1294.
Hattersley G., Owens J., Flanagan A.M. & Chambers T.J.. Macrophage colony stimulating factor (M-CSF) is essential for osteoclast formation in vitro, Biochem. Biophys. Res. Commun., 177, 1991, 526–531.[Medline]
Simonet W.S., Lacey D.L., Dunstan C.R., Kelley M., Chang M.-S., Lüthy R., Nguyen H.Q., Wooden S., Bennett L. & Boone T.. Osteoprotegerina novel secreted protein involved in the regulation of bone density, Cell., 89, 1997, 309–319.[Medline]
Tsuda E., Goto M., Mochizuki S., Yano K., Kobayashi F., Morinaga T. & Higashio K.. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis, Biochem. Biophys. Res. Commun, 234, 1997, 137–142.[Medline]
Yasuda H., Shima N., Nakagawa N., Mochizuki S.-I., Yano K., Fujise N., Sato Y., Goto M., Yamaguchi K. & Kuriyama M.. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG)a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro, Endocrinology., 139, 1998, 1329–1337.
Tan K.B., Harrop J., Reddy M., Young P., Terrett J., Emery J., Moore G. & Truneh A.. Characterization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and non-hematopoietic cells, Gene (Amst.)., 204, 1997, 35–46.[Medline]
Kwon B.S., Wang S., Udagawa N., Haridas V., Lee Z.H., Kim K.K., Oh K.O., Greene J., Li Y. & Su J.. TR1, a new member of the tumor necrosis factor receptor superfamily, induces fibroblast proliferation and inhibits osteoclastogenesis and bone resorption, FASEB J, 12, 1998, 845–854.
Jimi E., Nakamura I., Amano H., Taguchi Y., Tsurukai T., Tamura M., Takahashi N. & Suda T.. Osteoclast function is activated by osteoblastic cells through a mechanism involving cell-to-cell contact, Endocrinology., 137, 1996, 2187–2190.
Suda T., Nakamura I., Jimi E. & Takahashi N.. Regulation of osteoclast function, J. Bone Miner. Res, 12, 1997, 869–879.[Medline]
Jimi E., Nakamura I., Duong L.T., Ikebe T., Takahashi N., Rodan G.A. & Suda T.. Interleukin 1 induces multinucleation and bone-resorbing activity of osteoclasts in the absence of osteoblasts/stromal cells, Exp. Cell Res, 247, 1999, 84–93.[Medline]
Fuller K., Wong B., Fox S., Choi Y. & Chambers T.J.. TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts, J. Exp. Med, 188, 1998, 997–1001.
Burgess T.L., Qian Y., Kaufman S., Ring B.D., Van G., Capparelli C., Kelley M., Hsu H., Boyle W.J. & Dunstan C.R.. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts, J. Cell Biol, 145, 1999, 527–538.
Merkel K.D., Erdmann J.M., McHugh K.P., Abu-Amer Y., Ross F.P. & Teitelbaum S.L.. Tumor necrosis factor mediates orthopedic implant osteolysis, Am. J. Pathol, 154, 1999, 203–210.
Pacifici R., Brown C., Puscheck E., Friedrich E., Slatopolsky E., Maggio D., McCracken R. & Avioli L.V.. Effect of surgical menopause and estrogen replacement on cytokine release from human blood mononuclear cells, Proc. Natl. Acad. Sci. USA., 88, 1991, 5134–5138.
Assuma R., Oates T., Cochran D., Amar S. & Graves D.T.. IL-1 and TNF antagonists inhibit the inflammatory response and bone loss in experimental periodontitis, J. Immunol, 160, 1998, 403–409.
Abu-Amer Y., Ross F.P., Edwards J. & Teitelbaum S.L.. Lipopolysaccharide-stimulated osteoclastogenesis is mediated by tumor necrosis factor via its p55 receptor, J. Clin. Invest, 100, 1997, 1557–1565.[Medline]
Pfeilschifter J., Chenu C., Bird A., Mundy G.R. & Roodman G.D.. Interleukin-1 and tumor necrosis factor stimulate the formation of human osteoclast-like cells in vitro, J. Bone Miner. Res, 4, 1989, 113–118.[Medline]
Lewis M., Tartaglia L.A., Lee A., Bennett G.L., Rice G.C., Wong G.H., Chen E.Y. & Goeddel D.V.. Cloning and expression of cDNAs for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species specific, Proc. Natl. Acad. Sci. USA., 88, 1991, 2830–2834.
Tartaglia L.A. & Goeddel D.V.. Two TNF receptors, Immunol. Today., 13, 1992, 151–153.[Medline]
Smith C.A., Farrah T. & Goodwin R.G.. The TNF receptor superfamily of cellular and viral proteinsactivation, costimulation, and death, Cell., 76, 1994, 959–962.[Medline]
Kruppa G., Thoma B., Machleidt T., Wiegmann K. & Kronke M.. Inhibition of tumor necrosis factor (TNF)-mediated NF-B activation by selective blockade of the human 55-kDa TNF receptor, J. Immunol, 148, 1992, 3152–3157.[Abstract]
Baldwin A.S. Jr.. The NF-B and IB proteinsnew discoveries and insights, Annu. Rev. Immunol, 14, 1996, 649–683.[Medline]
Finco T.S. & Baldwin A.S.. Mechanistic aspects of NF-B regulationthe emerging role of phosphorylation and proteolysis, Immunity., 3, 1995, 263–272.[Medline]
Verma I.M., Stevenson J.K., Schwarz E.M., Van Antwerp D. & Miyamoto S.. Rel/NF-B/IB familyintimate tales of association and dissociation, Genes Dev, 9, 1995, 2723–2735.
Tartaglia L.A., Ayres T.M., Wong G.H. & Goeddel D.V.. A novel domain within the 55 kd TNF receptor signals cell death, Cell., 74, 1993, 845–853.[Medline]
Tartaglia L.A., Rothe M., Hu Y.F. & Goeddel D.V.. Tumor necrosis factor's cytotoxic activity is signaled by the p55 TNF receptor, Cell., 73, 1993, 213–216.[Medline]
Suda T., Jimi E., Nakamura I. & Takahashi N.. Role of 1,25(OH)2D3 in osteoclast differentiation and function, Methods Enzymol, 282, 1997, 223–235.[Medline]
Jimi E., Nakamura I., Ikebe T., Akiyama S., Takahashi N. & Suda T.. Activation of NF-B is involved in the survival of osteoclasts promoted by interleukin-1, J. Biol. Chem, 273, 1998, 8799–8805.
Kong Y.Y., Yoshida H., Sarosi I., Tan H.L., Timms E., Capparelli C., Morony S., Oliveira-dos-Santos A.J., Van G. & Tie A.. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis, Nature., 397, 1999, 315–323.[Medline]
Takeda S., Yoshizawa T., Nagai Y., Yamato H., Fukumoto S., Sekine K., Kato S., Matsumoto T. & Fujita T.. Stimulation of osteoclast formation by 1,25-dihydroxyvitamin D requires its binding to vitamin D receptor (VDR) in osteoblastic cellsstudies using VDR knockout mice, Endocrinology., 140, 1999, 1005–1008.
Sheehan K.C., Pinckard J.K., Arthur C.D., Dehner L.P., Goeddel D.V. & Schreiber R.D.. Monoclonal antibodies specific for murine p55 and p75 tumor necrosis factor receptorsidentification of a novel in vivo role for p75, J. Exp. Med, 181, 1995, 607–617.
Arch R.H., Gedrich R.W. & Thompson C.B.. Tumor necrosis factor receptor-associated factors (TRAFs)—a family of adapter proteins that regulates life and death, Genes Dev, 12, 1998, 2821–2830.
Yeh W.-C., Shahinian A., Speiser D., Kraunus J., Billia F., Wakeham A., de la Pompa J.L., Ferrick D., Hum B. & Iscove N.. Early lethality, functional NF-B activation, and increased sensitivity to TNF-induced cell death in TRAF2-deficient mice, Immunity., 7, 1997, 715–725.[Medline]
Wong B.R., Josien R., Lee S.Y., Vologodskaia M., Steinman R.M. & Choi Y.. The TRAF family of signal transducers mediates NF-B activation by the TRANCE receptor, J. Biol. Chem, 273, 1998, 28355–28359.
Galibert L., Tometsko M.E., Anderson D.M., Cosman D. & Dougall W.C.. The involvement of multiple tumor necrosis factor receptor (TNFR)–associated factors in the signaling mechanisms of receptor activator of NF-B, a member of the TNFR superfamily, J. Biol. Chem, 273, 1998, 34120–34127.
Kim H.H., Lee D.E., Shin J.N., Lee Y.S., Jeon Y.M., Chung C.H., Ni J., Kwon B.S. & Lee Z.H.. Receptor activator of NF-B recruits multiple TRAF family adaptors and activates c-Jun N-terminal kinase, FEBS Lett, 443, 1999, 297–302.[Medline]
Darnay B.G., Ni J., Moore P.A. & Aggarwal B.B.. Activation of NF-B by RANK requires tumor necrosis factor receptor–associated factor (TRAF) 6 and NF-B–inducing kinase. Identification of a novel TRAF6 interaction motif, J. Biol. Chem, 274, 1999, 7724–7731.
Lomaga M.A., Yeh W.C., Sarosi I., Duncan G.S., Furlonger C., Ho A., Morony S., Capparelli C., Van G. & Kaufman S.. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling, Genes Dev, 13, 1999, 1015–1024.
Naito A., Azuma S., Tanaka S., Miyazaki T., Takaki S., Takatsu K., Nakao K., Nakamura K., Katsuki M., Yamamoto T. & Inoue J.I.. Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice, Genes Cells., 4, 1999, 353–362.[Abstract]
Cao Z., Xiong J., Takeuchi M., Kurama T. & Goeddel D.V.. TRAF6 is a signal transducer for interleukin-1, Nature., 383, 1996, 443–446.[Medline]
Morony S., Capparelli C., Lee R., Shimamoto G., Boone T., Lacey D.L. & Dunstan C.R.. A chimeric form of osteoprotegerin inhibits hypercalcemia and bone resorption induced by IL-1β, TNF-, PTH, PTHrP, and 1,25(OH)2D3, J. Bone Miner. Res., 14, 1999, 1478–1485.[Medline]
Tsukii K., Shima N., Mochizuki S., Yamaguchi K., Kinosaki M., Yano K., Shibata O., Udagawa N., Yasuda H., Suda T. & Higashio K.. Osteoclast differentiation factor mediates an essential signal for bone resorption induced by 1,25-dihydroxyvitamin D3, prostaglandin E2, or parathyroid hormone in the microenvironment of bone, Biochem. Biophys. Res. Commun, 1246, 1998, 337–341.
Ammann P., Rizzoli R., Bonjour J.P., Bourrin S., Meyer J.M., Vassalli P. & Garcia I.. Transgenic mice expressing soluble tumor necrosis factor–receptor are protected against bone loss caused by estrogen deficiency, J. Clin. Invest, 99, 1997, 1699–1703.[Medline]
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Facebook 
Reddit 
Technorati 
Twitter What's this?
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| TABLE OF CONTENTS |
|
